Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series
In this case series, eptacog beta was safe, effective, and economical as first-line therapy, treatment of refractory BEs, management of perioperative bleeding, or prophylaxis in haemophilia patients with inhibitors.
Authors
- Guy A. Young (ORCID: https://orcid.org/0000-0001-6013-1254)
- Michael Recht (ORCID: https://orcid.org/0000-0002-2805-1016)
- Osman Khan (ORCID: https://orcid.org/0000-0002-4386-4015)
- Glaivy Batsuli (ORCID: https://orcid.org/0000-0002-0122-9320)
- Andrea Dvorak
- Kimberley Youkhana (ORCID: https://orcid.org/0000-0002-3188-4465)
- Yasmina L. Abajas (ORCID: https://orcid.org/0000-0001-7278-7357)
- Suchitra Acharya
- Duc Quang Tran (ORCID: https://orcid.org/0000-0002-6347-4452)
- Robert F. Sidonio (ORCID: https://orcid.org/0000-0002-9509-9415)
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Southern California (US)
- Northwell Health (US)
- Children's Hospital of Los Angeles (US)
- Emory University (US)
- SUNY Upstate Medical University (US)
- Yale University (US)
- National Hemophilia Foundation (US)
- Cohen Children's Medical Center (US)
- Children's Healthcare of Atlanta (US)
- OU Health
Publication Details
- Journal
- Haemophilia
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1111/hae.15094
- Citations
- 4
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- National Heart, Lung, and Blood Institute